QV Investors Inc. Has $15.50 Million Position in Solventum Corporation $SOLV

QV Investors Inc. lowered its stake in shares of Solventum Corporation (NYSE:SOLV) by 2.6% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 204,392 shares of the company’s stock after selling 5,400 shares during the period. Solventum comprises about 1.5% of QV Investors Inc.’s investment portfolio, making the stock its 23rd biggest holding. QV Investors Inc. owned 0.12% of Solventum worth $15,501,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Rossby Financial LCC acquired a new stake in shares of Solventum during the 1st quarter valued at $25,000. Strengthening Families & Communities LLC boosted its stake in shares of Solventum by 376.8% during the 1st quarter. Strengthening Families & Communities LLC now owns 329 shares of the company’s stock valued at $25,000 after buying an additional 260 shares during the period. Barrett & Company Inc. boosted its stake in shares of Solventum by 206.2% during the 2nd quarter. Barrett & Company Inc. now owns 398 shares of the company’s stock valued at $30,000 after buying an additional 268 shares during the period. IMG Wealth Management Inc. acquired a new stake in shares of Solventum during the 2nd quarter valued at $31,000. Finally, Hara Capital LLC acquired a new stake in shares of Solventum during the 1st quarter valued at $38,000.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on SOLV. Jefferies Financial Group assumed coverage on shares of Solventum in a research note on Thursday, September 11th. They set a “hold” rating and a $80.00 target price for the company. Wells Fargo & Company lifted their price objective on shares of Solventum from $79.00 to $82.00 and gave the company an “equal weight” rating in a research note on Monday, September 15th. Morgan Stanley raised shares of Solventum from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $80.00 to $103.00 in a research note on Tuesday, July 15th. Piper Sandler reaffirmed an “overweight” rating and issued a $94.00 price objective (up previously from $87.00) on shares of Solventum in a research note on Friday, August 8th. Finally, Wall Street Zen lowered shares of Solventum from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, September 9th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $84.89.

Solventum Stock Performance

Shares of SOLV opened at $71.49 on Friday. The company has a market capitalization of $12.40 billion, a PE ratio of 33.10, a price-to-earnings-growth ratio of 2.91 and a beta of 0.50. Solventum Corporation has a one year low of $60.70 and a one year high of $85.92. The company has a debt-to-equity ratio of 2.14, a current ratio of 1.22 and a quick ratio of 0.86. The company’s fifty day moving average price is $72.62 and its 200 day moving average price is $72.19.

Solventum (NYSE:SOLV) last announced its earnings results on Thursday, August 7th. The company reported $1.69 EPS for the quarter, topping the consensus estimate of $1.45 by $0.24. The firm had revenue of $2.16 billion for the quarter, compared to the consensus estimate of $2.12 billion. Solventum had a net margin of 4.52% and a return on equity of 29.93%. The business’s quarterly revenue was up 3.8% on a year-over-year basis. During the same quarter last year, the firm posted $1.56 EPS. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. As a group, analysts expect that Solventum Corporation will post 6.58 earnings per share for the current year.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.